Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC

Christopher Sweeney, MBBS
Published: Wednesday, Dec 13, 2017



Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Both docetaxel and abiraterone work well, says Sweeney, but the issue is getting both drugs to achieve maximum benefit. Abiraterone is easier to tolerate since it is a hormonal therapy whereas docetaxel has a higher treatment burden.

Combining both regimens with a hormonal therapy shows similar benefit, explains Sweeney, which makes determining which regimen to give first a challenge.
 


Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Both docetaxel and abiraterone work well, says Sweeney, but the issue is getting both drugs to achieve maximum benefit. Abiraterone is easier to tolerate since it is a hormonal therapy whereas docetaxel has a higher treatment burden.

Combining both regimens with a hormonal therapy shows similar benefit, explains Sweeney, which makes determining which regimen to give first a challenge.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x